Background
==========

Bariatric surgery represents a very effective method in the treatment of morbid obesity and related complications. Bariatric procedures induce major changes in the structure and function of the gastrointestinal tract leading to increased propensity to early and late dumping syndromes (DS) and nutritional deficiencies ([@bib1]). The latest UK national bariatric surgery registry from 2014 reports that from 12 869 women who had bariatric surgery between 2011 and 2013, nearly 70% were of childbearing age ([@bib2]), and these numbers are likely to rise since the prevalence of obesity increases. Fertility improves following bariatric surgery due to improved ovulation rates linked with weight loss; however, women are advised to avoid pregnancy for 12--24 months after bariatric intervention to reduce the risk of intrauterine growth retardation caused by the ongoing catabolic state ([@bib3]). To our knowledge, data on pregnancy numbers after bariatric surgery in the UK are currently not available.

Pregnancy constitutes a state of increased insulin resistance. Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed during the second or third trimester of pregnancy that was not clearly overt prior to gestation. It is linked with an increased risk of adverse outcomes for the mother and for the baby ([@bib4]). A significant proportion of women who had bariatric intervention, despite having lost significant amount of weight, would still have a body mass index (BMI) \>30 kg/m^2^ at the time of booking appointment or would have had previous history of GDM thus fulfilling the current National Institute for Health and Care Excellence (NICE) criteria for GDM screening ([@bib5]). A standard screening and diagnostic test for GDM, the 75 g 2-h oral glucose tolerance test (OGTT) is considered to be risky in patients after bariatric surgery due to its potential to cause DS as a result of altered glycaemic responses. Alternative approaches such as capillary glucose monitoring or the use of continuous glucose monitoring (CGM) are currently being debated ([@bib6]). In addition, once diagnosed, GDM in women after bariatric surgery constitutes a challenging clinical condition requiring multidisciplinary management with surgical, medical, obstetric and dietetic input with currently little evidence-based guidelines available ([@bib3]).

FreeStyle Libre Flash glucose monitoring system (FL) (Abbott Diabetes Care, Maidenhead, UK) represents a variation of CGM that has been recently introduced into clinical practice. It consists of a sensor that measures interstitial glucose (IG) levels at closed spaced intervals with a storage capacity of 8 h of IG data and of a reader with a monitor. In order to get a coherent IG profile, the user is asked to swipe the reader over the sensor at least every 8 h. IG data are displayed on the monitor of the reader together with IG trends. FL thus provides a useful and less costly alternative to standard CGM despite its recognised limitations such as inability to set alarms for high or low IG levels and a recognised tendency to lower-than-expected IG values in lower glucose ranges compared to the reference method ([@bib7]).

Case presentation
=================

A 26-year-old Caucasian female with history of morbid obesity (pre-surgery BMI 44.3 kg/m^2^) and GDM in her two previous pregnancies underwent Roux-en-Y gastric bypass (RYGB) surgery and became pregnant four months later. The patient had a background of polycystic ovarian syndrome, endometriosis, laparoscopic right ovarian cystectomy, appendectomy and vitamin D deficiency. She also developed mild cholestasis of pregnancy and was treated with ursodeoxycholic acid. There was also a history of complex social circumstances and domestic abuse. There was no family history of obesity, diabetes, GDM or any other endocrine condition in her first-degree relatives. Her brother and grandfather from mother's side had a history of lung emphysema. She has received the standard dietary education and counselling provided by the bariatric dietician team for people undergoing bariatric interventions at Sheffield Teaching Hospitals NHS Foundation Trust before and subsequently after her bariatric surgery. This included provision of detailed verbal and written information regarding necessary dietary modifications, vitamin and micronutrient supplementation together with the recommendation of avoiding pregnancy for 12--24 months after the bariatric surgery. During the course of pregnancy, she has been taking vitamin and micronutrient supplementation (WLS Forte and Calcium Plus, FitForMe, Rotterdam, Netherlands) and in addition, a cholecalciferol 800 IU tablet per day.

As expected, she continued to lose weight in the months following the bariatric surgery, which continued during the course of pregnancy ([Fig. 1](#fig1){ref-type="fig"}). Figure 1Weight chart of the 26-year-old lady with history of Roux-en-Y gastric bypass surgery who became pregnant shortly after. Times of bariatric intervention and approximate time of conception are indicated with arrows.

Due to the previous history of GDM and bariatric surgery, the patient was offered capillary blood glucose monitoring at her booking appointment at 11th week of gestation (11/40), instead of the usual 2-h 75 g OGTT test. The recorded blood glucose (BM) values were diagnostic of GDM ([@bib6]) ([Table 1A](#tbl1){ref-type="table"}) and metformin was started at 15/40. BM values continued to be elevated on metformin ([Table 1B](#tbl1){ref-type="table"}), and insulin (Humulin I and Humalog (Eli Lilly)) was added 2 weeks later. Table 1Example of capillary blood glucose profiles on diet alone (A) and on metformin (B).**Fasting BM1 h postPre-lunch1 h postPre-dinner1 h post**A. Diet alone **6.3\*8.4**4.3**8.36.39.1** **5.48.45.49.56.510.1**B. On metformin **6.07.27.09.36.38.3** 4.26.35.0**14.38.010.2**[^1][^2]

At 19/40, this lady was admitted under the care of the Obstetrics and Gynaecology team with persistent vomiting. A week prior to admission (18/40), she began to record BM readings in the hypoglycaemic range that were symptomatic, with a tremor and increased sweating. Metformin and insulin were stopped at 19/40, but the post-prandial and nocturnal hypoglycaemia persisted. She had no history of chronic liver disease, and her liver function tests were normal apart from a mild elevation of bile acids in the range of 20--37 µmol/L (reference range (RR): 0--14 µmol/L) throughout the 3rd trimester of her pregnancy in keeping with the diagnosis of cholestasis of pregnancy. Her renal function was normal.

Investigation
=============

Laboratory investigations showed a blood glucose value of 2.2 mmol/L with appropriately low insulin levels (14.8 pmol/L,RR: 17.8--173 pmol/L) and C-peptide levels (113 pmol/L, RR: 298--2350 pmol/L), negative IgG insulin antibodies and 09:00 h cortisol value of 658 nmol/L, indicating an intact hypothalamic--pituitary--adrenal axis.

Treatment
=========

Diagnosis of late DS, most likely in combination with an early dumping phase, was established, and this lady received appropriate dietary advice from the bariatric dietetic team. She was advised to take frequent small-portioned meals, with the exclusion of high glycaemic index (GI) food and a preference for low GI food. Avoidance of liquid carbohydrates and drinking fluids with meals ([@bib1], [@bib3]) was recommended. She found it difficult to adhere to dietary recommendations and treated hypoglycaemia with fast-acting carbohydrates resulting in subsequent hypoglycaemia and disturbed sleep with excess daytime tiredness. FL was introduced at 22/40 in order to avoid frequent nocturnal finger prick BM measurements and as an educational tool with the aim to help the patient to identify hypoglycaemic triggers ([Fig. 2A](#fig2){ref-type="fig"}). Figure 2Interstitial glucose (IG) profiles uploaded from the FreeStyle Libre Flash glucose monitoring system. (A) IG profiles with dietary interventions. (B) IG profiles with overnight (00:00--07:00 h) i.v. dextrose infusions at variable rates as indicated. (C) IG profiles at the time when the patient has been gradually weaned off the overnight i.v. dextrose infusions. Line in red indicates IG \<4 mmol/L. \* indicates capillary blood glucose measurement.

Despite these measures, this lady continued to experience ongoing symptomatic hypoglycaemia that she was able to treat independently. Despite very low IG and BM readings (finger prick BM readings marked in [Fig. 2](#fig2){ref-type="fig"} with \*), there was no history of collapse, seizure or loss of consciousness. Disturbed sleep continued to have negative impact on her wellbeing. At 25/40, a decision was made to prevent nocturnal hypoglycaemia with continuous intravenous dextrose infusion overnight (00:00--07:00 h) ([Fig. 2B](#fig2){ref-type="fig"}). Poor compliance with dietary recommendations persisted despite ongoing support from the diabetes specialist nurses and bariatric dieticians. The patient declined a trial of acarbose due to concerns about potential risks to the unborn baby and was resistant to the suggestion of discharge with community support. This was substantiated by the fear of inability to treat her hypoglycaemia when on her own and not being able to look after her 2 young children. Gradually, intravenous dextrose infusions were discontinued ([Fig. 2C](#fig2){ref-type="fig"}), and the patient was discharged home at 29/40.

Following discharge, this lady did not attend an appointment with the diabetes team and she returned her FL device shortly after. She was reviewed in the antenatal clinic in later stages of her pregnancy (32/40), and because of elevated post-prandial BM values metformin (32/40) and later insulin (Humalog) were re-introduced (33/40). Hypoglycaemias were less prominent and resolved completely at 34/40. The estimated fetal weight (EFW), which was on the 50th centile during the earlier stages of pregnancy declined at later stages resulting in EFW at 5th centile at 33/40 ([Fig. 3](#fig3){ref-type="fig"}). Head circumference (HC) and abdominal circumference (AC) followed a similar trend. Figure 3Antenatal weight chart. Gestational stage in week is on the *X* axis, fundal height at the left *Y* axis and estimated weight by scan on the right *Y* axis.

Outcome and follow-up
=====================

The patient was readmitted under the care of the Obstetrics and Gynaecology team at 34/40 due to reduced fetal movements and an emergency caesarean section was indicated at 35 + 1/40. She gave birth to a healthy baby girl with a birth weight of 2100 g.

After delivery, the patient continued to monitor her BMs with finger prick testing, and her BM readings remained within the normal range with no further occurrence of hypoglycaemia. She was invited for a fasting plasma glucose test at 6 weeks postnatally, but did not attend to this or any further appointments.

Discussion
==========

RYGB intervention is reported to result in DS in approximately 40% of patients, and it has previously been suggested that the presence of DS was essential for weight reduction, a hypothesis that has been refuted by further prospective studies ([@bib8]). DS is characterised by vasomotor and GI symptoms caused by altered gastric emptying and subsequent rapid exposure of the small intestine to nutrients ([@bib1]). Early DS is triggered by rapid passage of hyperosmolar content into the small bowel causing excessive release of GI hormones and shift of fluids into the GI lumen. It presents with abdominal pain, bloating, diarrhoea and vasomotor symptoms such as palpitations, flushing, sweating or tachycardia. Late DS is characterised by symptoms of hypoglycaemia and occurs typically between 1 and 3 h after meal ingestion ([@bib1]). Rapid gastric emptying leads to expeditious glucose absorption from the small bowel leading to initial hyperglycaemia. Subsequent peak insulin secretion perpetuated by increased glucagon-like peptide 1 levels eventually causes hypoglycaemia ([@bib1], [@bib9]).

The advent of CGM technology enabled observation of abnormal glycaemic profiles in non-pregnant women after RYGB surgery. These are characterised by early, high and short-lasting IG peaks returning back to normal values before the usual time points for BM measurements after the 75 g OGTT (1 or 2 h post glucose challenge) ([@bib10]). Interestingly, a subsequent study found very similar CGM profiles in pregnant women after RYGB ([@bib11]). The peak IG value was reached at 54 ± 9 min and the percentage of time spent with IG values above 140 mg/dL (7.8 mmol/L) was similar to that observed in women with GDM ([@bib11]). These findings indicate that the standard 75 g OGTT test is of poor diagnostic value of GDM in women post bariatric surgery. The other concern about the OGTT in this population is that the rapid absorption of dextrose can precipitate DS as discussed earlier.

Dietary modifications represent the mainstay of the management of late DS -- patients are advised to avoid refined carbohydrates and increase the intake of high-GI food, which should be taken in multiple small portions throughout the day. Avoidance of drinks taken with food and recumbent position whilst eating are also recommended ([@bib1], [@bib3]). If dietary measures are not sufficient, use of acarbose, octreotide and diazoxide have been reported ([@bib1], [@bib3]). However, usage of these agents is limited by the lack of well-controlled studies examining their safety in pregnant women. In refractory cases, more invasive measures have been reported -- continuous enteral feeding or a re-do surgery ([@bib1], [@bib3]). The patient from our report was aware of the paucity of safety data for these agents in pregnancy and refused to take any for this reason.

In our case, an emergency C-section at 35 + 1/40 was indicated due to reduced fetal movements and a baby girl with a small-for-gestational-age birth weight of 2100 g was delivered. A large observational study from Sweden compared the outcomes of 670 pregnancies in women who had undergone bariatric surgery with control pregnancies matched for the mother's pre-surgery BMI, age, parity, smoking history, educational level and delivery year ([@bib12]). Pregnancies after bariatric surgery were associated with higher risk for small-for-gestational-age infants and shorter gestation, but the risk of pre-term birth was not significantly different ([@bib12]). The outcome of the pregnancy from our case therefore partially reflects these large cohort observations.

We cannot provide a compelling explanation as to why this patient's hypoglycaemic episodes started towards the end of the first trimester, neither can we explain why they stopped completely in the 34th week of her pregnancy, and she has remained asymptomatic until the present time. We can presume that pregnancy soon after the bariatric intervention contributed to the way how her symptoms presented. The pathophysiology of DS is not yet fully understood in the non-pregnant individuals either ([@bib1]). We know from clinical observation that DS are common after pregnancy and can present a real diagnostic and therapeutic challenge ([@bib3]). Normal pregnancy is a state of insulin resistance (IR) that gradually increases throughout its course with rising plasma insulin concentrations in an attempt to maintain normoglycaemia ([@bib13]). We can therefore hypothesise that increased IR in later stages of pregnancy can trigger a higher post-prandial insulin secretion leading to subsequent hypoglycaemia (late dumping syndrome) in pregnant women with history of bariatric surgery, but further research will be required to confirm this hypothesis. Very recently, case reports of pregnant women with history of bariatric surgery suffering from dumping syndrome have been reported, and they seem to follow a similar time pattern with the occurrence of hypoglycaemic symptoms in 24th week of pregnancy in both cases ([@bib14], [@bib15]) and a nearly complete remission of symptoms after the delivery in one of the cases ([@bib15]). Authors of the other case report do not comment on the presence or absence of symptoms after delivery ([@bib14]). On the other hand, observational studies in pregnant women with type 1 diabetes show an increased risk of severe hypoglycaemia in 1st trimester and pregnancy-related intrinsic factors are postulated to play a role ([@bib16]). Our patient did not experience any hypoglycaemic episodes during 1st trimester of her pregnancy, however.

Finally, the indications for the use of FL system in our patient were to avoid frequent nocturnal finger prick BM measurements that interfered with her sleep and as an educational tool with the aim to help her to identify hypoglycaemic triggers. The use FL had undoubtedly positive impact on the above, however, the ability to continuously check real-time IG levels led to a degree of anxiety and stress when IG readings were less than 4 mmol/L despite her being oligosymptomatic or asymptomatic on most occasions. The patient was very keen to receive inpatient care despite reassurances that she could safely be discharged. She had a complex social and psychological background, which caused additional distress during her admission. This led to a perceived dependence on midwifery staff. She used the data from FL as evidence that she was still having episodes of hypoglycaemia and leverage to extend her admission. We would therefore advise caution in CGM usage in individuals where excessive data may cause additional distress.
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[^1]: Figures in bold are indicative of gestational diabetes mellitus (GDM).

[^2]: \*All figures are reported in mmol/L.
